Key points from article :
UK-based AstronauTx, a biotech startup, raises $61m to develop novel Alzheimer's drugs.
Their focus is on novel drugs that aim to correct the disrupted physiology of the brain, particularly by enhancing astrocyte functions.
The funds will support small-molecule drug development for clinical trials targeting Alzheimer’s symptoms and causes.
Although specific details about their approach are limited, AstronauTx's website mentions targeting pathological proteins like β-amyloid, tau, and α-synuclein.
AstronauTx's mission extends to improving the clearance of toxic species from the brain, with the goal of enhancing memory consolidation and metabolic efficiency for brain function.
In addition to the significant investment, AstronauTx has formed strategic partnerships to identify new treatments by modulating a unique ion channel target.
